{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:14:22Z","timestamp":1789978462462,"version":"4.0.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.transci.2017.08.013","type":"journal-article","created":{"date-parts":[[2017,8,26]],"date-time":"2017-08-26T20:48:12Z","timestamp":1503780492000},"page":"671-676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Immunoadsorption in neurological disorders"],"prefix":"10.1016","volume":"56","author":[{"given":"Satoru","family":"Oji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2017.08.013_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1744-9987.1998.tb00102.x","article-title":"Immusorba TR and Immusorba PH: basics of design and features of functions","volume":"2","author":"Yoshida","year":"1998","journal-title":"Therap Apher"},{"key":"10.1016\/j.transci.2017.08.013_bib0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/10731198909118273","article-title":"Extracorporeal immunoadsorption with IM-PH or IM-TR column","volume":"17","author":"Yamazaki","year":"1989","journal-title":"Biomater Artif Cells Artif Organs"},{"key":"10.1016\/j.transci.2017.08.013_bib0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1526-0968.2003.00010.x","article-title":"Immusorba TR and PH","volume":"7","author":"Hirata","year":"2003","journal-title":"Therap Apher Dial"},{"key":"10.1016\/j.transci.2017.08.013_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0165-5728(89)90042-8","article-title":"Plasma exchange with selective immunoadsorption of anti-acetylcholine receptor antibodies","volume":"22","author":"Somnier","year":"1989","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.transci.2017.08.013_bib0025","first-page":"M207","article-title":"Safety, stability, and effectiveness of immunoadsorption under membrane plasmapheresis treatment for myasthenia gravis","volume":"36","author":"Hosokawa","year":"1990","journal-title":"ASAIO Trans"},{"key":"10.1016\/j.transci.2017.08.013_bib0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2017.08.013_bib0035","first-page":"283","article-title":"Immunoadsorption and plasma exchange in multiple sclerosis: complement and plasma protein behaviour","volume":"19","author":"Palm","year":"1991","journal-title":"Biomater Artif Cells Immobil Biotechnol"},{"key":"10.1016\/j.transci.2017.08.013_bib0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/ndt\/14.2.419","article-title":"Crow\u2013Fukase syndrome \u2013 immunoadsorption plasmapheresis effectively lowers elevated interleukin-6 concentration","volume":"14","author":"Ako","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2017.08.013_bib0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2008.05.026","article-title":"Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients","volume":"201\u2013202","author":"Baggi","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.transci.2017.08.013_bib0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1620\/tjem.210.307","article-title":"Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica","volume":"210","author":"Takahashi","year":"2006","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.transci.2017.08.013_bib0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-065X.1998.tb01217.x","article-title":"Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis","volume":"164","author":"Vincent","year":"1998","journal-title":"Immunol Rev"},{"key":"10.1016\/j.transci.2017.08.013_bib0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.transci.2017.08.013_bib0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/brain\/123.1.116","article-title":"Guillain\u2013Barr\u00e9 syndrome with antibody to a ganglioside, N-acetylgalactosaminyl GD1a","volume":"123","author":"Kaida","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.transci.2017.08.013_bib0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1212\/CPJ.0b013e31826af23e","article-title":"Paraneoplastic syndromes and autoimmune encephalitis: five new things","volume":"2","author":"Rosenfeld","year":"2012","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.transci.2017.08.013_bib0075","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458512443917","article-title":"Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica","volume":"18","author":"Isobe","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.transci.2017.08.013_bib0080","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3109\/00207454.2011.596293","article-title":"Evaluation of serum IgG subclass concentrations in myasthenia gravis patients","volume":"121","author":"Liu","year":"2011","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.transci.2017.08.013_bib0085","first-page":"115","article-title":"Immunoglobulin G subclass distribution of autoantibodies to gangliosides in patients with Guillain\u2013Barr\u00e9 syndrome","volume":"109","author":"Ilyas","year":"2001","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"10.1016\/j.transci.2017.08.013_bib0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.transci.2017.08.013_bib0095","series-title":"Current advances in therapeutic plasmapheresis","first-page":"83","article-title":"Comparison of protein-A and tryptophan-conjugated polyvinyl alcohol gel columns with an anti-human immunoglobulin antibody absorber","author":"Jimenez-Klingberg","year":"1996"},{"key":"10.1016\/j.transci.2017.08.013_bib0100","first-page":"510","article-title":"A case of myasthenia gravis with anti-MuSK antibodies showing a dramatic improvement with plasma exchange","volume":"45","author":"Suzuki","year":"2005","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.transci.2017.08.013_bib0105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1526-0968.2003.00011.x","volume":"7","author":"Hirata","year":"2003","journal-title":"Therap Apher Dial"},{"key":"10.1016\/j.transci.2017.08.013_bib0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.transci.2016.01.003","article-title":"Adverse events in apheresis: an update of the WAA registry data","volume":"54","author":"M\u00f6rtzell Henriksson","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2017.08.013_bib0115","first-page":"127","article-title":"Application of LDL-apheresis and immunoadsorption in kidney diseases","volume":"49","author":"Su\u0142owicz","year":"2004","journal-title":"Rocz Akad Med Bialymst"},{"key":"10.1016\/j.transci.2017.08.013_bib0120","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/1744-9987.12467","article-title":"Removal characteristics of immunoadsorption with the immusorba TR-350 column using conventional and selective plasma separators","volume":"20","author":"Ohkubo","year":"2016","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2017.08.013_bib0125","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/vox.12191","article-title":"The effect of immunoadsorption with the Immusorba TR-350 column on coagulation compared to plasma exchange","volume":"108","author":"Koessler","year":"2015","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2017.08.013_bib0130","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2017.08.013_bib0135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/cen3.12343","article-title":"Future treatment for Guillain\u2013Barr\u00e9 syndrome","volume":"7","author":"Kuwabara","year":"2016","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.transci.2017.08.013_bib0140","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s004150050506","article-title":"Indicators of dysautonomia in severe Guillain\u2013Barr\u00e9 syndrome","volume":"246","author":"Pfeiffer","year":"1999","journal-title":"J Neurol"},{"key":"10.1016\/j.transci.2017.08.013_sbref0145a","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/brain\/118.3.597","article-title":"Guillain\u2013Barr\u00e9 syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies","volume":"118","author":"Ho","year":"1995","journal-title":"Brain"},{"key":"10.1016\/j.transci.2017.08.013_sbref0145b","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1474-4422(13)70215-1","article-title":"Axonal Guillain\u2013Barr\u00e9 syndrome: concepts and controversies","volume":"12","author":"Kuwabara","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0150","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/brain\/awh083","article-title":"Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera","volume":"127","author":"Willison","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.transci.2017.08.013_bib0155","first-page":"3","article-title":"Anti-ganglioside antibody and neuropathy: review of our research","volume":"3","author":"Yuki","year":"1998","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.transci.2017.08.013_bib0160","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome","volume":"9","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transci.2017.08.013_bib0165","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1744-9987.2009.00730.x","article-title":"Guillain\u2013Barr\u00e9 syndrome treated by membrane plasma exchange and\/or immunoadsorption","volume":"13","author":"Marn Pernat","year":"2009","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2017.08.013_bib0170","first-page":"431","article-title":"Immunoadsorption therapy for a child with Guillain\u2013Barr\u00e9 syndrome subsequent to Mycoplasma infection: a case study","volume":"27","author":"Arakawa","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.transci.2017.08.013_bib0175","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1272\/jnms.69.557","article-title":"Plasma immunoadsorption therapy for Guillain\u2013Barr\u00e9 syndrome: critical day for initiation","volume":"69","author":"Takei","year":"2002","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.transci.2017.08.013_bib0180","first-page":"979","article-title":"Immunoadsorption therapy with TR-350 (tryptophan column) for Guillain\u2013Barr\u00e9 syndrome: investigation including serum antiganglioside antibody assay","volume":"40","author":"Araki","year":"2000","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.transci.2017.08.013_bib0185","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1744-9987.1997.tb00051.x","article-title":"Two patients with acute Guillain\u2013Barr\u00e9 syndrome treated with different apheresis methods","volume":"1","author":"Uetakagaito","year":"1997","journal-title":"Ther Apher"},{"key":"10.1016\/j.transci.2017.08.013_bib0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0887-8994(98)00010-1","article-title":"Immunoadsorption therapy in Guillain\u2013Barr\u00e9 syndrome","volume":"19","author":"Hirai","year":"1998","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0195","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1526-0968.2004.00138.x","article-title":"Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain\u2013Barr\u00e9 syndrome","volume":"8","author":"Okamiya","year":"2004","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2017.08.013_bib0200","first-page":"621","article-title":"Chronic inflammatory polyradiculoneuropathy","volume":"50","author":"Dyck","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.transci.2017.08.013_bib0205","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/brain\/110.6.1617","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases","volume":"110","author":"McCombe","year":"1987","journal-title":"Brain"},{"key":"10.1016\/j.transci.2017.08.013_bib0210","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0000000000002418","article-title":"Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"Devaux","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.transci.2017.08.013_bib0215","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1756285612457215","article-title":"An update on the management of chronic inflammatory demyelinating polyneuropathy","volume":"5","author":"Gorson","year":"2012","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.transci.2017.08.013_bib0220","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000331011","article-title":"Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment","volume":"66","author":"Galldiks","year":"2011","journal-title":"Eur Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0225","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/jnnp.72.5.644","article-title":"Immunoadsorption inferior to plasma exchange in a patient with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"72","author":"Hadden","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.transci.2017.08.013_bib0230","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","article-title":"Myasthenia gravis and the neuromuscular junction","volume":"26","author":"Querol","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0235","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0240","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.transci.2017.08.013_bib0245","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-musk antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.transci.2017.08.013_bib0250","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.transci.2017.08.013_bib0255","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.transci.2017.08.013_bib0260","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0265","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2017.08.013_bib0270","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"K\u00f6hler","year":"2011","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2017.08.013_bib0275","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.transci.2017.08.013_bib0280","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0285","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.transci.2017.08.013_bib0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5692\/clinicalneurol.55.41","article-title":"Successful treatment of neuromyelitis optica spectrum disorder by early initiation of plasma exchange","volume":"55","author":"Koda","year":"2015","journal-title":"Rinsho Shinkeigaku (Clin Neurol)"},{"key":"10.1016\/j.transci.2017.08.013_bib0295","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","article-title":"Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels","volume":"9","author":"Kim","year":"2013","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jca.21324","article-title":"Immunoadsorption therapy for neuromyelitis optica spectrum disorders long after the acute phase","volume":"30","author":"Kobayashi","year":"2015","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2017.08.013_bib0305","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/1756285616646332","article-title":"Immunoadsorption in patients with neuromyelitis optica spectrum disorder","volume":"9","author":"Faissner","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.transci.2017.08.013_bib0310","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0315","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0320","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1756285610385608","article-title":"Evolving expectations around early management of multiple sclerosis","volume":"3","author":"Gold","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.transci.2017.08.013_bib0325","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11940-015-0345-6","article-title":"Therapeutic management of severe relapses in multiple sclerosis","volume":"17","author":"Bevan","year":"2015","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0330","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s00415-016-8105-4","article-title":"Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses","volume":"263","author":"Faissner","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0335","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1742-2094-9-80","article-title":"Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis","volume":"9","author":"Koziolek","year":"2012","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.transci.2017.08.013_bib0340","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000447059","article-title":"Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoadsorption \u2013 observational multicenter study with 147 patients","volume":"75","author":"Schimrigk","year":"2016","journal-title":"Eur Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0345","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1212\/WNL.59.8.1224","article-title":"Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients","volume":"59","author":"Tenembaum","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.transci.2017.08.013_bib0350","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11940-012-0170-0","article-title":"Treatment of acute disseminated encephalomyelitis","volume":"14","author":"Pohl","year":"2012","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0355","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1055\/s-0033-1355412","article-title":"Multimodal therapy of recurrent severe acute disseminated encephalomyelitis: the role of immunoadsorption","volume":"225","author":"Beyersdorff","year":"2013","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.transci.2017.08.013_bib0360","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/brain\/105.3.481","article-title":"Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study","volume":"105","author":"Al-Din","year":"1982","journal-title":"Brain"},{"key":"10.1016\/j.transci.2017.08.013_bib0365","first-page":"83","article-title":"An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome","volume":"118","author":"Yuki","year":"1993","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.transci.2017.08.013_bib0370","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/jnnp-2012-303060","article-title":"Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis: epidemiological and clinical characteristics","volume":"83","author":"Koga","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.transci.2017.08.013_bib0375","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.034","article-title":"Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller\u2013Fisher syndrome\/Bickerstaff brain stem encephalitis overlap syndrome","volume":"23","author":"Stetefeld","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.transci.2017.08.013_bib0380","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000345847","article-title":"A case of fisher-bickerstaff syndrome overlapped by Guillain\u2013Barr\u00e9 syndrome","volume":"4","author":"Fujii","year":"2012","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0385","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0390","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.22297","article-title":"Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia","volume":"69","author":"Lancaster","year":"2011","journal-title":"J. Ann Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0395","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ene.12389","article-title":"Tryptophan immunoadsorption for the treatment of autoimmune encephalitis","volume":"22","author":"K\u00f6hler","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.transci.2017.08.013_bib0400","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1212\/NXI.0000000000000207","article-title":"Immunoadsorption therapy in autoimmune encephalitides","volume":"3","author":"Dogan Onugoren","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050217301647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050217301647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T04:27:53Z","timestamp":1535430473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050217301647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1473050217301647"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2017.08.013","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoadsorption in neurological disorders","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2017.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}